HPV 16 - eller 18- relateret CIN 2/ 3 og AIS (Protokol 015, FUTURE II), HPV 6 -, 11 -, 16 -, eller 18- relateret persisterende infektion (Protokol 007) og HPV 16- relateret persisterende infektion (Protokol 005).
The primary efficacy endpoints included HPV 6-, 11-, 16-, or 18-related vulvar and vaginal lesions (genital warts, VIN, VaIN) and CIN of any grade (Protocol 013, FUTURE I), HPV 16- or 18-related CIN 2/ 3 and AIS (Protocol 015, FUTURE II), HPV 6-, 11-, 16-, or 18-related persistent infection (Protocol 007), and HPV 16-related persistent infection (Protocol 005).